Brainsway’s deep-TMS study in Obsessive Compulsive Disorder (OCD) Patients produces positive final results

Brainsway, located in Jerusalem, is preparing a submission to the FDA to market the device for Obsessive Compulsive Disorder (OCD) .

Its deep-TMS treatment led to statistically significant and meaningful improvements in patients suffering from OCD.

Patients who received active treatment were significantly better than those who received sham treatment.

For more information, see:

http://www.nasdaq.com/press-release/brainsway-announces-positive-final-results-of-its-deep-tms-multicenter-study-in-obsessive-20170612-00800

 

Show Buttons
Share On Facebook
Share On Twitter
Share On Google Plus
Share On Linkedin
Hide Buttons